Press

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

Jun 19 • 4 min read

CORAL GABLES, Fla., June 18, 2024 /PRNewswire/ — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry. The article is titled, “Efficacy and Safety of Esmethadone (REL-1017) in Patients…

Largest Study of Psychedelic Medicine, with 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-Home Ketamine Therapy

Jun 14 • 3 min read

AUSTIN, Texas, June 14, 2024 /PRNewswire/ — Mindbloom, the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for…

Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares

Jun 13 • 3 min read

VANCOUVER, BC, June 12, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announces that, further to its press release dated June 3, 2024, it has completed its previously announced C$1.0 million bridge financing (the “Financing“). Pursuant to the Financing, Negev Capital Fund One, LP (“Negev“),…

Psyched Wellness Developing Amanita Muscaria Gummies for Sale in the USA

Jun 13 • 2 min read

Toronto, Ontario–(Newsfile Corp. – June 13, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce it will be releasing a new product this summer…

Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

Jun 12 • 3 min read

MindBio Therapeutics Corp. reported positive secondary data from its world-first take-home microdosing depression trial using MB22001 completed earlier this year. Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-week treatment course with MB22001. This includes a 52% reduction in anxiety (HAM-A), and self-reported reductions in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435